61192-65-2

Upstream product

• 99-81-0 4-Nitrophenacyl bromide 
• 6388-74-5 p-Nitrophenyloxirane 
• 1393901-42-2 2-(4-nitrophenyl)-4-tosylmorpholine 
• 21719-25-5 N-(2-hydroxy-2-(4-nitrophenyl)ethyl)-4-methylbenzenesulfonamide 

Downstream Products

• 1286738-75-7 2-(4-nitrophenyl)morpholine-4-carboxylic acid tert-butyl ester 
• 1002726-96-6 2-(4-aminophenyl)morpholine-4-carboxylic acid tert-butyl ester 
• 1393901-43-3 tert-butyl 2-(4-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)morpholine-4-carboxylate 
• 1393901-44-4 2-(2-(2-(2-((4-(4-(tert-butoxycarbonyl)morpholin-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetic acid 
• 1393901-45-5 tert-butyl 2-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)morpholine-4-carboxylate 
• 1393900-60-1 2-(2-(2-(2-((4-(morpholin-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 

Relevant academic research and scientific papers

FAK AND FLT3 INHIBITORS

The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.